SCHEMBL4947604

SCHEMBL4947604

COc1cc(CNC(=O)[C@H](C)O)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.60
CYP1A2 P05177 4/20 0.60
CYP2D6 P10635 3/20 0.60
CYP2C9 P11712 3/20 0.60
CYP2C19 P33261 3/20 0.60
BLM P54132 2/20 0.60
PMP22 Q01453 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
TSHR P16473 2/20 0.60
POLB P06746 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17667848 1.00 CYP3A4 (0.60) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5197621 0.87 CYP1A2 (0.59) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL13883457 0.86 MTNR1A (0.60) TSHRLMNAALOX5MAPK1
SCHEMBL15339488 0.86 MEN1 (0.54) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL12899344 0.85 CYP1A2 (0.57) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL12884460 0.84 CYP1A2 (0.56) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL28368385 0.83 ERCC1 (0.79) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29224596 0.83 ERCC1 (0.74) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29224595 0.83 ERCC1 (0.74) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29224597 0.83 ERCC1 (0.74) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2013-10-24 US disclosed
WO-2012054528-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies GPR119, TAS1R2, TAS2R1 CYP3A4 4748/4885CYP1A2 4702/4885CYP2D6 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.